SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year of 2023 before market open on Wednesday, February 28, 2024.
The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Media Contact
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
Designed to address increasing demand for advanced medical connectors in growing specialties such as electrophysiology…
Designed to address increasing demand for advanced medical connectors in growing specialties such as electrophysiology…
SAN DIEGO--(BUSINESS WIRE)--ForeSee Medical Inc., a leading AI-powered risk adjustment software company, and Vim, a…
SAN DIEGO--(BUSINESS WIRE)--ForeSee Medical Inc., a leading AI-powered risk adjustment software company, and Vim, a…
Oeko-Institut appointed for third-party evaluation; stakeholder consultation will run June 6, 2025 - August 1,…
Facilities and care team tailored for patients with complex medical needs Specialized protocol includes optimized…